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Measurement of Nerve Growth Factor in Induced Sputum And
Exhaled Breath Condensate

Victor M. Nwiloh, M.D.

ABSTRACT
Several tests are available for evaluation of respiratory disorders but most of them
are invasive and associated with some risk or patient discomfort. Examples
include bronchoscopy (bronchoalveolar lavage, BAL) [1], venopuncture [2] and
sputum induction [3]. Noninvasive sampling of nongaseous substances contained
in expired air, collected as exhaled breath condensate (EBC) has been used to
detect inflammatory markers and by-products including nitric oxide and
arachidonic acid metabolites and proteins [4]. Nerve growth factor (NGF) is a
protein that has been implicated in neurogenic airway inflammation and this pilot
study aimed to develop a non-invasive approach for evaluation of allergic airway
inflammatory disease by measuring and comparing levels of NGF in the induced
sputum and EBC of ten (10) asthmatics and ten (10) non-asthmatics.
Though twenty (20) subjects were sampled, an unexpected event due to a
defective NGF kit inadvertently resulted in an unsuccessful analysis of fifteen
v

(15) sets of specimen (6 non-asthmatics and 9 asthmatics), limiting the study.
This study is significant because occupational lung diseases are the number one
work-related illness in the United States and occupational asthma is the most
common form [9]. Toluene diisocyanate (TDI) is the commonest cause of
occupational asthma and workers exposed to TDI vapor may develop
inflammatory conditions including asthma, rhinitis and nasal irritation [7].
Results: NGF was detected and measured only in sputum, with a mean NGF level
of 210 (210-210, range 0) in asthmatics and 164 (7-280, range 273) in nonasthmatics. Nonetheless, we failed to reject the null hypothesis (number 3).
Conclusion: This limited study did not have adequate power (power 11%) due to
the small sample size and thus lacks internal validity. Further studies are needed
using a larger sample size.
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INTRODUCTION
Diseases and the work environment
Bernardino Ramazzini, the "father of occupational medicine," was the first to
write about the effects of workplace hazards in causing some diseases over three hundred
years ago [8]. In the 21st century, toxic exposures and other unique hazards found in the
workplace continue to have a significant impact on public health.
A disease or disability resulting from the conditions of a person’s employment,
work, trade or occupation is called an occupational disease, illness or work related injury.
It usually but not always occurs following long exposure to a noxious substance or from
continuous repetition of certain acts. Occupational lung diseases are the commonest cause
of work-related illness in the United States [9]. In 2002, there were about 294,500 newly
reported cases of occupational illness in the private industry, and 22,000 newly reported
respiratory conditions [9]. Overall, 2.5 per 10,000 full time workers developed nonfatal
occupational respiratory diseases [9]. The total cost of occupational injuries and illnesses
in the United States exceeds $170 billion per year [9].

Occupational lung diseases
Occupational lung diseases are the number one work-related illness in the United
States based on the frequency, severity, and preventability of diseases [9]. Though these
illnesses are usually caused by prolonged exposure to irritating or toxic substances
1

which may result in acute or chronic respiratory ailments, severe single exposures can
also lead to chronic lung disease. Smoking may act synergistically to increase the
severity of these diseases.
Occupational lung diseases are often not curable, but are always preventable [9].
Improving ventilation, wearing protective equipment, changing work procedures, and
educating workers are the key factors for prevention [9]. Examples of the commoner
occupational lung diseases include occupational asthma (commonest), occupational lung
cancer, asbestosis, mesothelioma, byssinosis, coal workers’ pneumoconiosis, silicocis
and hypersensitivity pneumonitis [9].

Occupational asthma
Occupational asthma is defined as asthma caused by work exposure [10]. It is
characterized by recurrent episodes of respiratory symptoms, variable airflow
obstruction, airway hyperreactivity and chronic airway inflammation [10].
Chronic inflammation may lead to airway remodeling. The term "airway
remodeling" refers to structural changes that occur in conjunction with, or because of,
chronic airway inflammation and its consequences include incompletely reversible airway
narrowing, bronchial hyper-responsiveness, airway edema, and mucus hypersecretion,
which may predispose subjects with asthma to exacerbations and even death due to
airway obstruction.
Surveillance programs established around the world have determined that
diisocyanate chemicals are the most common cause of occupational asthma. In the United
States approximately 100,000 workers are exposed to these chemical compounds in the
2

workplace each year and 5-10% of these workers will develop occupational asthma. In
industrialized countries, occupational factors have been implicated in 9 to 15 % of all
cases of adult asthma [11, 12].
There are two types: (i) immunologic type, characterized by a latency period
before onset of symptoms and (ii) nonimmunologic type, which occurs after single or
multiple exposures to high concentrations of a workplace irritant material in the absence
of a latency period [13]. Work-aggravated asthma is also well defined, and is preexisting
or concurrent asthma exacerbated by workplace exposures [13]. Variant syndromes have
been described too [13]. Clinical history obtained with use of questionnaires has a high
sensitivity (87-92%) and low specificity (14-32%) for diagnosis, but is less reliable for
recognition of airway hyperresponsiveness. A methacholine challenge test is preferred for
this. In addition to assessment of airway hyperresponsiveness, noninvasive assessment of
airway inflammation can be used to diagnose occupational asthma.
The best treatment for occupational asthma is primary prevention by hazard
abatement in the form of removal of the offending agent and substitution of a nontoxic
agent. Strict exposure control is needed when asthma is induced by a workplace sensitizer
and this can be achieved preferably by engineering control to protect all employees in the
work area or respirator (personal protective equipment) use to protect specific
individuals. Rhinitis is associated with an increased risk of asthma regardless of atopic
status and occupational rhinoconjunctivitis can lead to occupational asthma [14].
Screening and monitoring for rhinitis and or rhinoconjunctivitis during preemployment physical examinations and as part of a health surveillance program may help
3

in early detection of sensitized workers and promote early intervention necessary to
prevent progression to occupational asthma. This would be expected to result in a
significant reduction in the incidence of occupational asthma.

Methods used to study respiratory diseases
Inflammation is a component of several diseases of the upper and lower
respiratory tract including rhinitis, asthma, chronic obstructive pulmonary disease and
bronchiectasis. Typically it is assessed directly by performing invasive procedures such
as bronchoalvelar lavage and bronchial biopsy or indirectly by venopuncture, though the
use of these procedures in clinical practice is limited. Another common and well
validated method is sputum induction which is non-invasive but often causes great
discomfort to patients [10]. As a result of this, researchers continued to search for
alternative methods of assessing airway inflammation that is neither invasive nor
uncomfortable.
Recently, two new noninvasive methods were introduced. First, is the
measurement of exhaled nitric oxide which reveals increased levels in the exhaled air
from asthmatic patients that can be decreased by corticosteroid therapy, however, a few
occupational studies that have been done to assess the its role in occupational asthma
revealed inconsistent results [10]. The usefulness of exhaled nitric oxide is the
investigation of occupational asthma is limited by confounding factors such as therapy
with inhaled steroids and smoking, thus it has a high sensitivity but low specificity [10].
The second noninvasive method is the detection of markers (e.g. isoprostanes and
4

aldehydes) and mediators (prostaglandins and leukotrienes) in exhaled breath condensate
[10]. Noninvasive sampling of nongaseous substances contained in expired air, which can
be collected as exhaled breath condensate (EBC) has been used to detect markers of
inflammatory processes including arachidonic acid metabolites and proteins.
Because serial measurements can be made with no harmful effects, it is possible that this
method could be useful in occupational medicine [10].
Both methods described above use exhaled air, which is usually warm and
humidified. Exhaled air contains gases, water vapor, and various volatile substances that
come from the airways and the fluid that lines the airways. Several of these dissolved
substances have been shown to be markers of airway disease and or inflammation.
Because exhaled air is easily obtained in a non-invasive manner with minimal discomfort
to patients, it has great potentials for routine use in clinical practice for screening and
diagnosing airway inflammation, as well as monitoring patient’s response to treatment.
However, measurements of markers in exhaled breath can vary based on the parameters
used to study them. Results may vary based on type of equipment used, the exhalation
duration, the method of acquiring samples, and the expiratory flow rate.

Nerve growth factor (NGF)
NGF is a neurotrophin produced locally in the human airways. Increasing
evidence suggests that NGF may also be an important inflammatory mediator [1]. The
first report that serum level of NGF was increased in human allergic inflammatory
diseases including asthma, rhinoconjunctivitis and urticaria-angioedema was in 1996.
5

Patients with more than one allergic disease had higher NGF serum values than those
with a single disease [2]. Healthy subjects also produce NGF in their airways but at lower
levels compared to persons with allergic airway disease.
In vitro studies have shown that NGF is synthesized and secreted by structural
cells (human lung fibroblasts, airway epithelial cells and smooth muscle cells) and cells
of the immune system (lymphocytes, monocytes, macrophages, eosinophils and mast
cells). NGF exerts a central role in the development, differentiation and function of
neuronal and immune cells [6]. NGF induces sensory and sympathetic hyper-innervation
of the airways, which leads to increased airway reactivity upon provocation with
capsaicin or using electrical field stimulation, and increased systematic and airway levels
of tachykinins can be induced by an allergen challenge in asthmatics.
Animal studies indicate that NGF alters sensory nerve function and promotes
allergic inflammation (via neurokinin 1, NK-1), bronchial hyper-reactivity and airway
obstruction (via neurokinin 2, NK-2) and regulation of tachykinin synthesis has been
implicated as the mediator [6]. The fact that these effects of NGF can be blocked by a
tachykinin receptor antagonist, coupled with the elevated levels of substance P (a
tachykinin) found in the lungs of asthmatics during an acute attack further support this.
Substance P has a high affinity for NK-1 receptors. Transient increases in substance P
protein have been demonstrated in sensory cell bodies innervating respiratory epithelium
of the nose or lung following antigen challenge , toluene diisocyanate (TDI) exposure,
viral infection and asphalt fume exposure [7]. Previous studies have shown that exposure
to TDI results in elevated NGF levels and this precedes the inflammatory changes [7].
6

NGF measurement in blood, bronchoalveolar lavage (BAL) fluid, nasal lavage
fluid, and sputum is well documented in the medical literature using invasive techniques
such as endoscopy, venopuncture and sputum induction [1,2,3,5]. However, a literature
review revealed no evidence of studies on NGF measurement in exhaled breath
condensate.

Research questions
1.) Can nerve growth factor (NGF) be measured in induced sputum and exhaled
breath condensate (EBC)?
2.) If so, how do levels differ between asthmatics and non-asthmatic subjects?

7

HYPOTHESIS
To study this, NGF is measured in exhaled breath condensate and induced sputum
while comparing asthmatics with non-asthmatics. The first Null hypothesis states that
NGF is not measurable in induced sputum. The first alternate hypothesis states that NGF
can be measured in induced sputum. The second Null hypothesis states that NGF is not
measurable in EBC. The second alternate hypothesis states that NGF can be measured in
EBC. The third Null hypothesis states that there is no difference in the levels of NGF
measured in the sputum of asthmatic persons compared to non-asthmatic persons. The
third alternate hypothesis states that higher levels of NGF can be measured in the sputum
of asthmatic persons compared to non-asthmatic persons. The fourth Null hypothesis
states that there is no difference in the levels of NGF measured in the EBC of asthmatic
persons compared to non-asthmatic persons. The fourth alternate hypothesis states that
higher levels of NGF can be measured in the EBC of asthmatic persons compared to nonasthmatic persons.
8

GOALS AND OBJECTIVES
This study aims to develop a non-invasive approach to evaluation of airway
inflammation and disease, especially in persons with allergic conditions using exhaled
breath condensate.

9

SIGNIFICANCE AND UTILITY OF RESEARCH
This study is unique because non-invasive techniques are currently not available for
routine measurement of NGF. If NGF is detected and consistently measured in EBC, this
may represent a safe, easy and non-invasive alternative approach for evaluation of
allergic airway inflammation and diseases. Furthermore, since rhinitis is associated with
an increased risk of asthma regardless of atopic status, screening and monitoring for
rhinoconjunctivitis as part of a preemployment physical and health surveillance program
may help in the early detection of possibly sensitized workers and promote early
intervention necessary to prevent progression to occupational asthma. The end result will
be a significant reduction in the incidence of occupational asthma. Furthermore,
measurement of NGF levels may be useful in the assessment of exposure in irritant
induced asthma (Reactive Airways Dysfunction Syndrome) and lastly, new drugs that
target NGF may be developed in the future for treatment of asthma.

10

MATERIALS AND METHODS
Overall study design
In this pilot study, the variable studied was asthmatic versus non-asthmatic status
and the outcome of interest was levels of the marker nerve growth factor (NGF) in
induced sputum and exhaled breath condensate. A cross sectional study design was
utilized where individual specimens were collected, processed, stored and analyzed to
obtain relevant data.
Twenty people were divided in two groups of ten. The first group was made up
of asthmatics with mild disease while the second group constituted non-asthmatics. The
study population was otherwise made up of healthy, non-pregnant persons aged 18-50
years old. Health was defined as having a negative history of heart disease, fever or
respiratory tract infection within 96 hours prior to participating, chronic lung disease and
moderate asthma or worse. Persons on daily maintenance therapy for asthma including
beta-2 agonist bronchodilators and steroids were excluded.

Facilities and equipment
The participants were seen at the College of Public Health at the University of
South Florida in the Breath Laboratory (MHH Room 323). The records were maintained
in a secured cabinet in this room. The key to access the laboratory was distributed by the
11

University of South Florida only to authorized personnel (obtained through the College of
Public Health). The necessary equipment discussed above that was needed to perform
this project was available in this room.

Participant recruitment
Healthy subjects were asked to volunteer for the study performed during a single
visit lasting approximately ninety minutes at the Breath Laboratory located in the College
of Public Health (MHH Room 323). Subjects who expressed a willingness to volunteer
were invited to the Breath laboratory and given information about the study aim,
procedure, risks and benefits, and the alternatives to the procedure. They were
questioned to demonstrate an understanding of all that was discussed. Throughout the
encounter subjects were encouraged to ask questions at any time. Afterwards, willing
subjects were then required to sign an informed consent before proceeding with the study.
They were monitored by a physician throughout the encounter by direct observation.
Prior to participating in the study and undergoing spirometry, subjects were advised not
to eat or drink anything and to refrain from strenuous exercise as recommended in the
American Thoracic Society (ATS) guidelines [15].

Study subjects and restrictions
Only normal healthy, non-pregnant people aged 18-50 years old and those with a
self reported history of mild asthma were invited to participate in the study with the
following exceptions. A history of heart disease, fever or respiratory tract infection within
12

96 hours prior to participating, chronic lung disease, moderate asthma or worse and daily
maintenance therapy for asthma with bronchodilators and steroids are all exclusion
criteria. Subjects were also required to refrain from strenuous exercise, food and drinks at
least one hour prior to the test as recommended by the American Thoracic Society [19].

Study questionnaire and eligibility
Each subject was required to fill out a pre-study questionnaire on the day of the
study after consenting to participate but prior to commencement of the study. Information
included on this form includes age, current symptoms, past medical history, allergies,
medications, smoking history and environmental exposure to second hand smoke.
During each visit, subjects were also given a brief exit questionnaire to assess for change
in symptoms and possible adverse effects from the study. (See Appendices A and B)
The medical history was elicited to determine health and eligibility criteria.
Subjects who fulfilled the eligibility criteria proceeded to undergo a brief physical
examination including auscultation of the lungs and heart. Those subjects who remained
eligible after questionnaire, interview, and physical examination were allowed to proceed
to get a baseline spirometry. To be eligible to participate in the remainder of the study,
all participants were required to have a forced expiratory volume in one second (FEV1)
equal or greater than 1.5L on spirometry.
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Subject safety considerations
Subject safety was given the utmost consideration in this study. Subjects were
advised that they could choose to stop or withdraw at any time without any consequence.
All subjects were healthy volunteers. The entire study was non-invasive. Physical
examination and initial medical screening questionnaires were reviewed directly by a
physician prior to commencement of study protocol. Only subjects who had normal
physical examination were allowed to continue in the study. Spirometry, which is
commonly used in clinical practice to assess lung function, was obtained as an eligibility
criterion. To obtain spirometry, subjects blew out through a disposable filter (to prevent
infection) using maximum effort after a maximal inhalation.
Measurement of exhaled breath condensate, which is currently still a research
tool, involved tidal breathing into the mouth piece of a cooling tube with a nose clip in
place. This results in the trapping of moisture in the breath by condensation. This process
was associated with less discomfort than spirometry and sputum induction.
During each visit, subjects were also given a brief exit questionnaire to assess for any
new symptoms or possible adverse effects from the study protocol.
Participation in this study did not affect the standard care subjects would
otherwise receive from their personal physicians unless abnormal finding were detected
on physical examination and or spirometry. Under those circumstances, the subject was
advised to consult with their personal physician. In the unlikely event that a subject
develops an adverse effect the study will be stopped immediately despite the fact that
most events would only be transient and subside within a few seconds to minutes of
14

stopping the activity. In the event of persistent symptoms including chest pain or
tightness, wheezing and dyspnea emergency equipment was available at all times during
the study to assist the subject until the arrival of appropriate emergency personnel. To
ensure patient safety, all subjects were directly observed by a physician who was ACLScertified during the entire study protocol. The sampling procedure was completely noninvasive.

Physical examination
A brief physical examination with emphasis on auscultation of the lungs and heart
was performed on all subjects prior to obtaining spirometry and proceeding with the rest
of the study protocol. Auscultation involves listening to the breath and heart sounds with
a stethoscope. Person with abnormal finding were deemed ineligible and immediately
excluded. Such persons were advised to seek necessary medical care from their personal
physician. Auscultation of the heart was performed for the sole purpose of subject safety.

Acquisition of spirometry
Spirometry a common clinical method used to assess lung function, was
performed as part of the inclusion criteria for the study. The Koko spirometer was used
and calibrated using a standard 3-liter syringe to ambient temperature, humidity, and
barometric pressure at least once a day on days when participants were examined. The
spirometer was additionally re-calibrated when at least six hours had elapsed since the
prior calibration or at the discretion of the examiner. The raw FEV1 and FVC
15

measurements obtained for each participant were automatically compared to their
predicted normal values based on age, ethnicity, weight, height and smoking status in
determining their percent of predicted values using parameters as set forth by Crapo et al.
The spirometry parameters examined on each study participant included FEV1,
FVC, FEV1/FVC ratio, and the flow-volume loop. At least three spirometric
measurements were obtained on each subject, with at least one flow-volume loop
showing good effort. Proper technique was ensured by evaluating the flow-volume curve
and continuance of the expiratory maneuver for at least six seconds according to ATS
criteria. A nose-clip was placed on the subject’s nose to occlude the nostrils during
spirometry so as to prevent nasal breathing and ensure accuracy. Subjects were asked to
forcibly exhale for at least six seconds through a disposable single-use filter after
maximal inspiration, followed by another maximal inhalation. The maneuver was
demonstrated to them to help achieve consistency.
Subject with abnormal spirometry measurements was notified of this information
and advised to consult their personal healthcare provider. They were subsequently
excluded from the study. All subjects with an FEV1/FVC ratio greater than 70% of
predicted, FEV1 greater than 1.5 L and a normal appearing flow-volume loop were
eligible for the study by spirometric criteria. In those participants who did not meet all of
these strict criteria, the overall clinical picture, including medical history and physical
examination were assessed individually to determine study eligibility. When eligibility
due to spirometry did not meet these strict criteria, Dr. Stuart Brooks (faculty advisor)
was consulted to determine whether the participant would be eligible for the study.
16

Adverse effects were unlikey to occur during this phase of the study because
subjects identified themselves as being in good health and the test was performed with
the patients comfortably seated in a room was temperature controlled. Nonetheless, there
was the slight possibility of unusual symptoms such as lightheadedness, dizziness, chest
pains, palpitations, or shortness of breath during the spirometry from overexertion in
breathing. As a precaution, subjects were instructed to stop, be seated, and notify the
physician examiner immediately if they experienced any symptoms at any time.

Specimen collection
The study was conducted in two parts. First, exhaled breath condensate (EBC)
was obtained and afterwards, sputum was collected via induction.
Exhaled breath condensate: The exhaled breath condensate was collected by using
a condenser, which permits noninvasive collection of the nongaseous components of the
expiratory air (EcoScreen; Jaeger, Wurzburg, Germany). The subjects were instructed to
breathe through a device with a mouthpiece and a two-way non-rebreathing valve, which
also serves as a saliva trap. Subjects wore a nose clip and were breathing at a normal
frequency and tidal volume for 10 minutes. If the subjects salivated they were instructed
to swallow. The condensate was collected in a collection cup at the base of the device and
transferred into a microtube for immediate storage at –70°C using a micropipette. As the
sample was taken non-invasively during tidal breathing, this method of sampling does not
influence the sample taken as observed with other methods such as bronchoalveolar
lavage or induced sputum.
17

Induced sputum: Prior to sputum induction, subjects were given clear and detailed
instructions because full cooperation was needed to obtain adequate samples. Full
resuscitation equipment was made available as recommended for specific and nonspecific bronchial challenge procedures. An ultrasonic nebulizer (DeVilbiss ProUltraNeb Large olume Nebulizer099HD) with an output of 1ml per minute (1 ml/min)
was used. Because of the risk of bronchoconstriction with use of hypertonic saline in
asthmatic subjects, pretreatment with a bronchodilator was done on all subjects using a
single dose of albuterol 2.5mg given over 3 minutes. Spirometry was repeated to ensure
no significant change in FEV1 before proceeding with administration of 3% saline over 7
minutes. 3% saline solution was administered via aerosol inhalation using a nebulizer and
afterwards yet another spirometry was done to monitor for FEV1 changes. The process
was stopped immediately if there was a fall in FEV1 of 20% or greater compared with the
post-bronchodilator value or if subjects developed symptoms including lightheadedness,
dizziness, chest pain or tightness, palpitations, dyspnea or wheezing.
Finally, subjects were seated at a negative pressure cubicle where sputum
expectoration was performed over a 5 – 10 minute period. The sputum was collected in a
petri dish and processed as stated in the literature [16] prior to storage at –70°C.
Collected sputum was checked for adequacy prior to processing by preparing a slide.
Slide preparation entailed making a sputum smear with a loop and heat fixing it. Slide
was stained with 1-2 drops of 1% methylene blue and allowed to stand for 1 minute
before washing off with water. Afterwards, the slide was air dried and examined under a
light microscope at 40x and 100x magnifications. An adequate specimen was defined as
18

one with visible inflammatory cells (neutrophils, basophils, monocytes, eosinophils etc)
and less than 50% squamous cells. Adequate sputum samples were immediately
processed. First, the sample was weighed, inspected grossly and findings were recorded.
The sputum portion of the sample (selected portion) was separated from saliva as
much as possible using forceps and transferred to a polystyrene tube and the weigh was
recorded. 10% dithiotreitol (DTT, Sigma chemical, St. Louis, MO, U.S.A.) equivalent to 4x
the weight of the selected portion was added and agitated in a vortex mixer for 15 seconds.
Afterwards the mixture was placed on a bench rocker for 15 minutes and DPBS equivalent
to the volume of DTT used was added. The mixture was placed on a bench rocker or an
additional 5 minutes. The mixture is then filtered through a 70 micrometer nylon
gauze/mesh and the weight of the filtrate was recorded. Finally, the filtrate was centrifuged
at 500 rpm for 5 minutes and the supernatant was aspirated with a micropipette and
transferred to eppendorf micro-tubes for storage at –70°C. The stored samples are later
analyzed for measurement of NGF using enzyme-linked immunosorbent assay (Promega,
Madison, WI, USA, ELISA).

Measurement of NGF
ELISA: The levels of NGF protein was quantified in 1:2 diluted sputum and EBC
samples, using a commercially available, highly sensitive NGF-specific two-site enzyme
linked immunosorbent assay (ELISA) – kit according to the procedure indicated by the
manufacturer (Promega, Madison, WI, USA). 96-well ELISA plates were coated with an
anti-NGF polyclonal antibody in a coating buffer (25mm carbonate buffer, pH 9.7).
19

Following an overnight incubation at 4 degrees centigrade, the plates were washed (20mm
Tris-HCl, 150mM NaCl with 0.05% (v/v) Tween® 20), and incubated in a blocking
buffer for 1hour. The diluted sputum and EBC samples and the standard recombinant
human NGF was then incubated in wells at room temperature for 6 hours, and washed
afterwards. The 2 samples and the recombinant NGF was diluted in the blocking buffer, as
recommended by the manufacturer. Rat monoclonal anti-NGF antibody (0.25mcg/ml) was
added for an overnight incubation at 4 degrees centigrade, and washed afterwards. After
washing, anti-rat horse radish peroxidase-conjugated immunoglobulin G (Ig G) was added
and incubated for 2.5 hours at room temperature.
Finally, the substrate (0.02% 3,3’, 5,5-tetramethylbenzidine and 0.01% hydrogen
peroxidase) was added and incubated for 10 minutes before stopping the colorimetric
reaction with 1N hydrochloric acid which changed the solution from blue to yellow. The
sample absorbance or optical density was measured at 450NM within 30 minutes of
stopping the reaction.

Data collection and analysis
Though a large study population would be required to appropriately assess the
research questions, the analysis of exhaled breath condensate (EBC) is an evolving research
concept and measurement of nerve growth factor (NGF) in EBC has not been reported in
the literature. This study was embarked upon as a pilot study with the intent to follow up
with a larger sample size in the event that NGF is detectable in significant amounts in EBC
and sputum.
20

Twenty eligible subjects were studied to provide insight to the following
research questions:
(1) Can nerve growth factor (NGF) be measured in induced sputum and exhaled
breath condensate (EBC)?
(2.) If so, how do levels differ between asthmatics and non-asthmatic subjects?
A power calculation was performed which was derived using alpha of 0.05 and
power of 80%. An estimated sample size of 64 is required to show a significant difference
in the mean of the two groups given the above parameters. In any study where there are two
groups being compared, the participants are ideally randomly assigned to each group.
However, random assignment is not possible when two distinct groups are being used such
as males versus females. A similar situation obtains in this study, where the two distinct
groups were asthmatics versus non-asthmatics.
The mean of each of the two groups in a study sample may be compared using a
Student’s t-Test, a parametric analysis, when the population studied is normally distributed.
When the population is not normally distributed, a non-parametric analysis must be used.
Non-parametric tests include the Wilcoxon Ranked-Sum Test or the Mann-Whitney U Test.
Statistical calculations were performed by inputting the data into Statistical
Analysis Software (SAS), which calculated the data automatically. For this study, SAS
was utilized to calculate descriptive statistics such as the mean, median, variance, standard
error of the mean, standard deviation, range, minimum and maximum values, skewness,
and kurtosis for the non-asthmatic group.
21

STUDY RESULTS
Exclusions
Two asthmatic subjects who expressed their willingness to participate in the study
were excluded because they were on daily maintenance therapy for asthma. Another nonasthmatic study volunteer was turned down because of ongoing acute bronchitis which
was being treated with antibiotics.
No one was excluded on account of abnormal auscultation during physical exam.
All the subjects had a normal cardiac exam with normal first and second heart sounds
with regular rate and rhythm and no murmurs, gallops or rubs. The lung exams revealed
normal vesicular breath sounds bilaterally with no crackles, wheeze or rhonchi. There
was no deformity on chest exam. All subjects had FEV1 greater than 2.5 L.

Study demographics
The following tables demonstrate the results of the demographic information that
was collected during the study.
Table 1. Study population
Groups

Numbers

Percentage

Asthmatics

1

20

Non-asthmatics

4

80
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Table 2. Age distribution

Age

19

25

29

32

39

Asthmatics

0

0

1

0

0

Nonasthmatics 1

1

0

1

1

Table 3. Sex distribution
Male

Female

Asthmatics

0

1

1

Non-asthmatics

3

1

4

Total

3

2

5

Medical Information
The following tables list the history of allergies and smoking, co-morbidities,
medications, allergens, physical exam findings and study adverse effects.
Table 4. History of Allergy
Asthmatics

Non-asthmatics

Positive history of allergy

1

0

Negative history of allergy

0

4
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Table 5. Smoking History

Asthmatics

Non-asthmatics

Never/non-smoker

1

3

Current smoker

0

0

Ex-smoker

0

1

Medical conditions

Asthmatics

Non-asthmatics

Grave’s disease

1

0

GERD

1

0

Hypertension

0

1

Deep Venous Thrombosis

0

1

Medications

Asthmatics

Non-asthmatics

Synthroid

1

0

Albuterol

1

0

Benadryl

1

0

Cimetidine

1

0

Lisinopril

0

1

Aspirin

0

1

Table 6. Co-morbidities

Table 7. Medications
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Data

Table 8. Nerve Growth Factor Measurement.

1

Asthmatic

Non-asthmatic

Asthmatic EBC

Non-asthmatic

Sputum (pg/ml)

Sputum (pg/ml)

(pg/ml)

EBC (pg/ml)

210

7

0

0

2

171

0

3

280

0

4

198

5

Figure 1: Mean sputum NGF levels in asthmatics and non-asthmatics
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Table 9. Statistical Analysis of Sputum Nerve Growth Factor levels for all subjects

Asthmatic

Non-asthmatic

N

1

4

Mean

210

164

Median

210

184.5

Standard Deviation

114.5

Variance

13103.3

Standard Error of the Mean

57.2

Skewness

-1.008

Kurtosis

1.837

Range

0

273

Minimum

210

7

Maximum

210

280

t-value 2.87
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DISCUSSION
Findings
This study was aimed at determining if NGF is measurable in induced sputum and
exhaled breath condensate and if so how do levels differ between asthmatics and nonasthmatics? Demographic data revealed that 5 subjects age 19 – 39 years old participated
in the study. Medical information review revealed a history of GERD and Grave’s
disease in the asthmatic while the non-asthmatics reported hypertension and deep venous
thrombosis.
The results revealed that NGF was measurable only in sputum. The mean value in
asthmatics was 210 pg/ml while non-asthmatics had a mean value of 164 pg/ml. The
independent t-test was used to analyze the data, and a t-value of 2.870 was obtained while
the critical value was 2.353 given alpha of 0.05. Though a mean difference of 46 was
found between asthmatic and non-asthmatic subjects, this is not statistically significant
and we fail to reject the null hypothesis. The power obtained was 0.1135 (11%), however
in view of the small sample size used (1 asthmatic and 4 non-asthmatics), the study
lacked adequate power. If a sample size of 20 was used as planned initially, the power
will only be raised to 23% (0.2288). The prestudy analysis estimated that a sample size of
64 is needed to obtain a power of 80% (0.80) for a mean difference of 0.5, given a
standard deviation of 1 and alpha set at 0.05. The type II error, beta (1-power) was 89%
(0.8865) but will be reduced to 77% with a sample size of 20.
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Implications

The implication gleaned from this study is that there is no significant difference in
the sputum NGF levels in asthmatics compared to non-asthmatics and we failed to reject
the null hypothesis. However, the study does not have adequate power due to the small
sample size. Though a previous study showed no significant difference in sputum NGF
levels (pg/ml) in persons with chronic cough including asthma (median 580; interquartile range 312 – 880) compared to healthy controls (median 516; inter-quartile range
296-772), some other studies suggest that higher levels of NGF are obtained in asthmatics
[19].
Twenty (20) sets of samples were collected and analyzed in 2 batches for this
study (Batch A: 5; Batch B: 15). The first batch was analyzed successfully; however the
second batch was inadvertently ruined at analysis by a bad NGF kit which was defective
from the manufacturer. Unfortunately, a new replacement kit was not immediately
available and in view of time constraint under the circumstance, the study had to be
reported with the limited data available. This incomplete study lacks internal validity.

Future Directions
In the future, improved micro-concentration collection techniques (lipholization)
and analytic chemistry methods could increase the likelihood of detecting NGF in EBC,
however NGF may be absent in EBC. Further research in this direction is needed.
Values obtained for NGF in sputum may have been similar to non-asthmatics
because only persons with stable mild asthma and normal spirometry were included in
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the study except for one subject. In future studies, asthmatic subject selection should be
based strictly on spirometric parameters and not just a self reported history.
Finally, future studies should be well designed with emphasis on random selection
of subjects, large sample size and objective criteria for defining asthmatic subjects.

Study Limitations
Limitations can have a negative effect on the validity of the study. This
incomplete study is limited by it’s small sample size and thus lacks internal validity. The
stronger the association is in nature, the easier it is to find with a small sample size. The
closer the true association is to the null value, the larger sample size you need to find it to
be statistically significant [17]. When the sample is too small, a study is more likely to
miss an association, increasing the likelihood of a Type II error [17]. A Type II error may
have been committed in this study where a weaker association could still be present and
would not be detected by this study.
Study biases may limit the value of a study. This study may have been limited by
selection bias. Though males and females from various racial backgrounds (Caucasian,
Blacks, Asians and Hispanics) were used in this study, all subjects were recruited from
within the University campus and were current or past undergraduate and graduate
students. Observer bias was also present as this was not a blind study. All of these can
limit the generalizability of the study [17.
Confounders can also affect a study. Several methods may be used to control for
confounders including restriction, randomization, and matching[17]. Multiple restrictions
29

were used in the study design to attempt to control for confounder but randomization was
not done because two distinct groups (asthmatics and non-asthmatics) were being
compared. Matching, though beneficial was not used either.
In performing statistical analyses where two distinct groups were compared, three
underlying assumptions were made: (1)Assumption of Normality, (2)Assumption of
Homogeneity of Variance, and (3)Assumption of Independence [18]. Statistical analyses
are most robust to violations of the Normality Assumption. Statistical analyses are
moderately robust to the Homogeneity of Variance Assumption. Statistical analyses are
the least robust to the Assumption of Independence, the most serious of the violations. In
this study, care was taken not to allow people who were genetically related to each other
participate in the study.
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CONCLUSION
Given the small sample size and the other limitations listed above, this pilot study
is limited in its value. NGF was not detected in EBC. Though a higher mean NGF was
observed in the sputum of asthmatics, we failed to reject the null hypothesis. NGF may
be truly absent in EBC otherwise improved analytic chemistry methods may enhance
detection of NGF in the future. Further studies are needed before NGF measurements in
sputum can be used routinely in clinical practice. A follow up study using a larger sample
size will increase the power and ensure internal validity and generalizability of the results
obtained.
Measurement of NGF in sputum may be useful in surveillance programs of
ccupational asthma and the estimation of dose from exposure with Reactive Airways
Dysfunction Syndrome (RADS). Study results observed in sputum may be used in
combination with other tools for the diagnosis of occupational asthma.
If elevated levels of NGF is detected in asthmatics, this will conform with other
studies done with BAL, nasal lavage and blood. I would expect allergic asthma to be
associated with higher levels of NGF compared to irritant induced asthma because it
involves sensitization and a latent period. Mild disease may not result in any significant
difference in NGF levels compared to non-asthmatics. Furthermore, coticosteroids
suppress NGF level elevation / response if given prior to exposure.
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Appendix A: Pre-study questionnaire
Subject number:_______
PRESTUDY QUESTIONNAIRE

Date _______________________________________

1) Gender:

Male

Female

(circle one)

2) What is your date of birth? ______________________

3) How old are you? _____________________________ years old.

4) Do you currently have, or have you ever had any of the following conditions
listed below? (Please circle YES or NO)

YES

NO

CHEST PAIN, PALPITATIONS, IRREGULAR HEART
BEAT, OR HEART DISEASE?

YES

NO

HIGH BLOOD PRESSURE?

YES

NO

ASTHMA
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YES

NO

BRONCHITIS, EMPHYSEMA, OR OTHER
LUNG OR BREATHING DISORDERS?

YES

NO

DIFFICULT OR HEAVY BREATHING?

YES

NO

A LARGE AMOUNT OF PHLEGM PRODUCTION

YES

NO

ANY ALLERGIES?

YES

NO

ARE YOU PREGNANT?

YES

NO

HISTORY OF HERNIA?

IF YOU HAVE CIRCLED YES TO ANY OF THE ABOVE QUESTIONS, PLEASE
EXPLAIN: ___________________________________________________________

___________________________________________________________

5) Do you have any health problems or past medical history of health problems that
you have seen a physician for? Please list them below.
1._________________________________________________________
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2. ________________________________________________________

3. ________________________________________________________

4. ________________________________________________________

5.________________________________________________________

6) Are you taking any medications? If so please list them below. (Including over the
counter medications)

1. ________________________________________________________

2. ________________________________________________________

3. ________________________________________________________

4. ________________________________________________________

5. ________________________________________________________

6. ________________________________________________________
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7. ________________________________________________________

7) At this point in time, to what degree do you note the following symptoms?

(a) Phlegm production:
___NONE

___VERY LITTLE

___MODERATE AMOUNT

___VERY MUCH

(b) Runny or irritated nose or nasal passages:
___NONE

___VERY LITTLE

___MODERATE AMOUNT

___VERY MUCH

(c) Throat irritation or burning sensation:
___NONE

___VERY LITTLE

___MODERATE AMOUNT

___VERY MUCH

(d) Sensation of a “weight” or tightness of the chest:
___NONE

___VERY LITTLE

___MODERATE AMOUNT

___VERY MUCH

(e) Feeling of chest pain, burning, or tightness:
___NONE

___VERY LITTLE

___MODERATE AMOUNT

___VERY MUCH

8) If you have ever smoked, please answer the following:

How many packs per day did you smoke? ________________________

For how many years did you smoke? ____________________________
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When did you stop smoking? __________________________________

9) On what date were you last ill? _____________________________________

10) What illness did you have? ________________________________________

Please circle YES or NO to the following questions:

a) Are you exposed to second hand smoke at home or at work?

YES

or

NO

b) Were you or are you exposed to any gases, dusts, or fumes at your job?
YES

or

NO

If so, please explain: ____________________________________________

_____________________________________________________________________

c) Do you ever wheeze or become short of breath?
YES

or

NO
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 This is the end of this questionnaire. Thank you for taking the time to fill it
out.
 Special thanks to Dr. Gwyn Crump for allowing the use of his questionnaire in
this study.
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Appendix B: Post-study questionnaire

Post-Study Questionaire

SUBJECT NUMBER: ________________________________________

Are you currently experiencing any of the following symptoms?
(Please Circle YES or NO)

(1) Difficult or heavy breathing? YES

NO

(2) Feeling of chest pain, tightness, pressure, or burning?
YES

NO

(3) Wheezing or increased cough? YES

NO

(4) Any new symptoms that were not present when you arrived
here today?

YES NO

(5) Any other unusual symptoms?

YES NO

Special Thanks To Dr. Gwyn Crump for developing the majority of this questionnaire!
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Appendix C: Flyer
You’re Are Invited To Participate.
What?
A $20.00 token will be given to each volunteer who completes the study for valuable time
spent participating.
This study makes measurements of the air breathed out by subjects. The tests will measure
lung function & a constituent of exhaled air and sputum called Nerve Growth Factor (NGF).
This research study involves getting a breathing treatment but is painless and non-invasive.
Who?
Healthy men and women with or without a history of asthma.
Candidates must be 18-50 yrs old and of any race.
Why?
The study is designed to examine whether a certain marker (NGF) found in the air we
normally breathe out is different in healthy asthmatics compared to non-asthmatics. Your
participation in this study may help develop a less invasive test for routine assessment of
allergic airway disorders such as asthma, which may enable healthcare providers to better
monitor worsening of disease or exacerbations. Hopefully, the results will benefit
science.
When?
The study requires only one visit and will last approximately ninety minutes.
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Where?
USF College of Public Health
If you may be interested or have any questions, please contact me (DR. VICTOR
NWILOH) at:
pager number: (813) 332-6925
cell phone number: (678) 472-2387
e-mail: vnwiloh@hsc.usf.edu
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Appendix D: Informed consent form

Informed Consent for an Adult
University of South Florida
Information for People Being Asked to Take Part in Research Studies
IRB Study # 103749

Doctors and researchers at University of South Florida (USF) study diseases and other
health problems people have. We try to find better ways to help treat these health
problems. To do this, we need the help of people who agree to take part in a research
study.
Title of Research Study: Measurement of Nerve Growth Factor in induced sputum and
exhaled brath condensate.
Persons in Charge of Study: Victor M. Nwiloh, MD; Stuart M. Brooks, MD and Thomas
Truncale, D.O.
Where the study will be done: University of South Florida, College of Public Health,
MHH Room 323
Who is paying for the study: Sunshine Education Research Center
Should you take part in this study?
This form tells you about this research study. You can decide if you want to take part in
it. You do not have to take part. Reading this form should help you decide if you want
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to take part in the study. If, at any time, you have any questions feel free to ask the
person explaining this study to you.
Before you decide:
•

Read this form.

•

Talk about this study with the study doctor or the person explaining the study. You
can have someone with you when you talk about the study.

•

Find out what the study is about.

This form explains:
•

The purpose of this research study.

•

What will happen during this study and what you will need to do.

•

The potential benefits of being in this study, if any.

•

The risks of having problems because you are in this study.

•

The answers to any questions you might have.

You can ask questions:
•

You may have questions this form does not answer. If you do, ask the study doctor as
you go along.

•

You don’t have to guess at things you don’t understand. Ask the people doing the
study to explain things in a way you can understand.

After you read this form, you can:
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•

Take your time to think about the information that has been provided to you.

•

Have a friend or family member read the form.

Talk it over with your regular doctor.

It’s up to you:
•

If you choose to be in the study, then you can sign the form.

•

If you do not want to take part in this study, do not sign the form.

Why is this research being done?
The purpose of this study is to find out if there is a difference between asthmatic and nonasthmatic subjects in relation to a certain substance in the air we breathe out called nerve
growth factor which is also found in induced sputum. This research could eventually lead
to the development of a non-invasive method for routine assessment of allergic airways
diseases such as asthma.
The air we breathe out is currently the subject of intense research. There are certain
substances in this air whose levels are affected by specific diseases associated with the
lungs. In this study, one of these substances in exhaled breath is called nerve growth
factor. Your exhaled breath will be collected into a single-use, clean, disposable tube that
has never been used before. Each tube is discarded after you have used it. Sputum is also
induced with a nebulizer and collected in a specimen bottle for measurement of nerve
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growth factor. Two groups of subjects will be examined in this study because persons
with allergic diseases such as asthma have been found to have significantly higher levels
of NGF in other tests.
Why are you being asked to take part?
You must be a healthy person within a certain age group to be eligible for the study. You
will not be eligible if you have had an acute exacerbation of asthma or febrile illness at
the time of evaluation or within the preceding 96 hours or if you are pregnant. You may
have had a recent respiratory tract disease if you have had any recent fever, chills,
coughing, shortness of breath or difficulty breathing, nasal congestion, runny nose, sinus
congestion or headache, colored phlegm or (green, yellow, brown, black, or red),
crackling or whistling sounds heard when you breathe, diagnosis by a doctor of
nose/sinus/lung infections, or recent treatment with antibiotics for any of these
symptoms. You may not be eligible if you have poorly controlled asthma or any other
diseases or health problems. We are asking you to take part in this study because you are
a healthy young person aged between 18-50 years. We want to find out if there is a
difference in the exhaled breath and induced sputum content of NGF between healthy
asthmatics and non-asthmatic subjects.
Your regular medical treatment will not actually be part of the research study. In fact
you will not be eligible for the study if you suffer from any significant heart or lung
disease or other significant medical problems. How long will you be asked to stay in
the study? You will be asked to spend no longer than 90 minutes in this study.
During this time you will be required to complete the screening questionnaires, perform a
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limited non-invasive physical examination, a breathing test and the study proper.
How often will you need to come for study visits?
A study visit is one you have with the study doctor. This visit is different than the visits
you make with your regular doctor. You will need to come for only one visit.
At this study visit, the doctor will obtain a questionnaire both before and after testing,
perform a brief physical exam consisting primarily of listening to your heart and lungs
using a stethoscope, and perform the breathing tests.
How many other people will take part?
About 30 people will take part in this study at USF.
Will the medical treatment you get from your regular doctor change if you take part in
this study?
The kind of treatment you now get from your regular doctor will not change because you
take part in this study. You will keep seeing your regular doctor. Your regular doctor
will give you the same kind of treatment you would get anyway, whether you take part in
the study or not.
If you need it, you can
•

Use other medicines prescribed that will help your disease.

•

Get any surgery you need.

•

You will need to talk to the study doctor about any surgery you have planned.
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Talk to your regular doctor about the treatments you may need.
If you have an emergency, you can get emergency care.
Other procedures can be used for measuring airway disease. These include bronchoscopy
with bronchoalveolar lavage/ bronchial biopsy (which are invasive), or sputum induction
(which can be less comfortable). These procedures, which can be ordered by your
regular doctor if needed clinically, will not be performed here.
What other choices do you have if you decide not to take part in this study?
The alternative to being part of this research study is not to participate in this study.
There will be no changes in your life. You will continue with your regular life style
and are instructed to visit your personal physician for any respiratory or nonrespiratory problem you were being followed for before the study. The same is true if
you decide to participate in the study.
If you decide you do not want to take part in this study that is okay. There are other
choices such as chest X-ray, chest CT, bronchoalveolar lavage, biopsy, or sputum
induction that are considered to be the current standard practices for diagnosing
airway disease.
How do you get started?
You must be within a certain age group to be eligible for the study. You must also be
healthy to participate in this study. Volunteers must be between ages 18 and 50. If you
decide to participate in this study, you will be required to review this informed consent,
discuss the study and your possible participation with the study doctor and decide
50

whether you are interested in participating. If you decide to take part in this study, you
will need to sign this consent form. This informed consent must be signed before any
study-related test or procedure can be done. After signing this informed consent,
screening tests will be completed to help determine if you meet the requirements to be in
the study. You will be asked to fill out questionnaires, undergo a limited physical
examination and perform a limited breathing test called spirometry. Screening tests are
tests done to see if you are able to be in the study. In order to qualify, you must record a
history of good health. You must record a negative questionnaire response for active
respiratory diseases. You must not be suffering from any heart condition.
There are different tests performed. These tests are considered non-invasive and do
not involve drawing blood or inserting tubes into your throat or nose.
We will do these screening tests:
1. Questionnaires: You will be asked to fill out questionnaires about your health,
ethnicity, and socioeconomic status. They will include medical questionnaires. A
post-study symptom questionnaire will also be given at the end of each visit.
2.

Physical Examination: Listening with a stethoscope to your chest and abdomen.

3.

Spirometry: This is a common, frequently used and accepted medical test for
evaluating how your lungs are working. Abnormal spirometry may indicate that
you have a lung disease such as asthma, emphysema, chronic bronchitis, and
other diseases. The test involves taking in a deep breath and then blowing out
into a tube as hard and as fast as you can. The spirometer measures the amount
and speed with which you forcibly exhale your deep breath.
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You will be notified if your spirometry test results are abnormal and advised to see your
personal physician.
The test results will come back right away. At the end of each of these screening tests,
you and the research team will decide whether or not you should be in the study.
What will you need to do to get ready for this study?
You will need to refrain from strenuous physical exercise (such as running, jogging,
working out with exercise equipment, participating in sports, or doing any heavy physical
labor), eating, or drinking for a minimum of one hour prior to the visit.
You must be within a certain age group to be eligible for the study. You must also be
healthy to participate in this study. Volunteers must be between ages 18 and 50. If you
decide to participate in this study, you will be required to review this informed consent,
discuss the study and your possible participation with the study doctor and decide
whether you are interested in participating. This informed consent must be signed before
any study-related test or procedure can be done. After signing this informed consent,
medical tests will be completed to help determine if you meet the requirements to be in
the study. You will be asked to fill out a questionnaire, undergo a physical examination
and perform a breathing test. In order to qualify, you must record a negative respiratory
questionnaire response to treatment for active respiratory diseases. You must not be
suffering from any major cardiovascular condition.
There are different tests performed. These tests are considered non-invasive and do
not involve drawing blood or inserting tubes into your throat or nose.
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What will happen during this study?
Only healthy, non-pregnant subjects without a history of heart or other diseases ages 1850 years old will be invited to participate. You will be asked to verify that they have not
had any signs of recent asthma exacerbation or febrile illness including upper or lower
respiratory tract infections. This would include any recent fever, chills, coughing,
shortness of breath or difficulty breathing, nasal congestion, runny nose, sinus congestion
or headache, colored phlegm or (green, yellow, brown, black, or red), crackling or
whistling sounds heard when you breathe, diagnosis by a doctor of nose/sinus/lung
infections, or recent treatment with antibiotics for any of these symptoms. At a minimum
of 1 hour prior to visit, subjects will be instructed not to eat or drink or participate in
strenuous exercise.
If you decide to participate :
During the visit, you will be asked to volunteer for the study. If you volunteer, you will
be given information about the study procedure, the risks, the benefits, and the
alternatives to the procedure. Then you will be asked if you have any questions and
demonstrate an understanding of everything discussed. If you still agree to proceed, you
will be asked to sign an informed consent. You will be taken to the Breath Laboratory at
the College of Public Health (MHH Room 323) and seated comfortably in an airconditioned room.
You will be asked to complete a questionnaire including symptoms, medical history to
determine “health” and age. Those who fulfill the criteria of age and being “healthy” will
be asked to participate in the study. You will then undergo brief physical examination
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including auscultation. You will be directly watched by a physician throughout the
remainder of the study via direct observation.
Limited spirometry (including FEV1, FVC, and FEV1/FVC ratio), which is part of a
common method done in hospitals and clinics to check lung function, will be done to help
verify that your breathing is normal. A loose-fitting device resembling a clothespin will
be placed on the nose during the study to obtain better spirometry results. You will be
asked to forcibly exhale into a disposable single-use tube using maximum effort after
maximal inhalation. Anyone who has abnormal spirometry measurements will be
notified of this information and advised to consult a healthcare provider and disqualified
for the remainder of the study.
Adverse effects are extremely uncommon during this phase of the study because subjects
are young/ healthy individuals and the room is temperature controlled. You will be seated
during the spirometry, and this phase of the study is brief in duration, nonetheless, there
is the remote possibility of unusual symptoms such as lightheadedness, dizziness, chest
pains, palpitations, or shortness of breath during the spirometry from overexertion in
breathing. As a precaution, you will be instructed to notify the physician examiner
immediately if you experience any symptoms at any time. Following this, auscultation
will be performed again and you will be given another brief symptom questionnaire to
make sure you have no adverse effects from spirometry.
Next, the actual study exhaled breath testing, which is strictly part of the research, will be
performed to measure the amount of nerve growth factor in the breath. You will be asked
to breathe out through a disposable plastic mouthpiece connected to a filter at a constant
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rate of flow after a maximal inspiration (which is where you take as deep a breath in as
you can to fill your lungs with as much air as possible). Afterwards, sputum induction
will be initiated using a nebulizer and samples will be collected in a specimen bottle.
Following this, the investigator will again perform a brief physical examination using a
stethoscope to listen to your heart and lungs and you will be given another brief symptom
questionnaire to make sure you have no adverse effects after the study.
Some study visits may be longer or shorter than ninety minutes depending primarily on
both the equipment and subject variability in breathing.
You will be asked to verify the absence of symptoms prior to leaving.
We will study two groups of people:
People in one group will be asthmatics. People in the other group will be of nonasthmatics.
Usually subjects may exhale different levels of markers that we can measure in the
breath.
We want to examine whether levels of the marker nerve growth factor in exhaled breath
condensate and induced sputum is different between asthmatics and non-asthmatics.
Right now, we do not know for sure if the measurement of nerve growth factor in exhaled
breath condensate and induced sputum will accurately measure allergic lung disease. We
are doing this study to find out if the measurement of nerve growth factor in your breath
is differs amongst asthmatics and non-asthmatics.
If the measurement is not accurate, you may still have airway or lung disease that is
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undetected by the study. You should consult your own physician regardless of the study
results if you have any concerns or experience any symptoms at any time.
During this study, here is what you will need to do:
Subjects will be instructed to refrain from eating, drinking, or strenuous exercise for at
least one hour prior to the visit.
Will you be paid for taking part in this study?
We will pay you for the time you volunteer while being in this study. You will receive a
total of twenty dollars for completion of the study.
What will it cost you to take part in this study?
The study will pay the costs of limited physical exam (primarily auscultation), limited
spirometry, and the experimental nerve growth factor measurement.
You will not have to pay the fees for tests in this study that are not a part of regular
medical care for your disease/condition.
Those subjects that do not have a parking permit for on-campus parking will have to pay
for any parking costs incurred as required from the University of South Florida by taking
part in this study.
You will have to pay for your regular care or any other costs. Your insurance plan should
cover your regular costs. Your insurance plan will not have to pay for study costs of
limited physical exam, limited spirometry, or nerve growth factor measurement.
What are the potential benefits if you take part in this study?
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We don’t know if you will get any health benefits by taking part in this study. We do not
know if nerve growth factor measurement will help in diagnosing airway or lung
diseases. That is why we are doing this study.
This research study should help us learn whether nerve growth factor measurement will
help in diagnosing allergic airway or lung diseases.
Since a medical questionnaire, limited physical exam, and limited spirometry will be
performed, overt abnormalities detected by your examiner will be relayed to you. You
will be instructed to consult your regular doctor regarding these findings.
No matter what, we will learn more about exhaled breath nerve growth factor levels in
asthmatics and non-asthmatics. We will learn more about whether differences do or do
not exist. What we learn may help others who are actively studying nerve growth factor
in exhaled breath for potential use in clinical settings.
What are the risks if you take part in this study?
The treatment might not help.
Right now we do not know for sure if the measurements are consistent. Because of this,
you will have to consult your regular physician if you are experiencing any shortness of
breath, other symptoms, or have any concerns about disease status. If you do, your
condition/disease may get worse.
There may be adverse effects.
You may have problems because of the procedure used in this study. These problems are
called adverse effects. Some adverse effects are just a bother. Others could harm you.
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There may be some adverse effects that we don’t know about yet.
Here are the known adverse effects that could happen with this study:
This study poses minimal risk to you. Spirometry is a standard, routine physical test
commonly performed in hospitals and some clinics. It is a noninvasive and relatively
safe procedure and involves the requirement for maximal expiratory effort. Thus, there is
a minimal risk that you may breathe too hard during the forced expiratory maneuvers.
This could result in: [1]“hyperventilation”, where too much carbon dioxide is blown off
in a short period of time or [2]excessive physical exertion. Immediate effects you could
experience from “hyperventilation” or excessive physical exertion may include
lightheadedness, dizziness, chest pain or pressure, rapid heart beat, or shortness of breath.
These usually resolve upon discontinuing the procedure. You are instructed to
immediately notify the examiner if any symptoms result. A determination by the
examiner of whether or not to continue with the study will be made on an individual
basis. At any time, both you and the examiner have the right to stop the study for any
reason. If you were to continue despite these symptoms, loss of consciousness or
cardiopulmonary arrest could result in rare cases, requiring emergency treatment and/or
hospitalization. In such rare cases, permanent effects could result.
Patients with history of any type of hernia are excluded from the study since they could
potentially aggravate the hernia using maximal expiratory effort.
The procedure for collecting exhaled breath nerve growth factor is very similar to the
procedure for spirometry, except that the subject is asked to breathe out at a slow regular
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rate instead of the forced maximal exhalation required in spirometry. Thus, it poses even
less risk and discomfort to the subject than spirometry.
Private medical information will be collected during the study to find out your health
status. The health information is being collected only as a guide for participation in the
study. The questionnaires used in the study must remain confidential. To maintain your
confidentiality, the questionnaires and recorded data from the study will be kept in a
locked file cabinet. Access to the material will only be made to the investigators of the
study. Also, as an additional measure to ensure confidentiality, each person will be given
a subject number. This will be the only identifier listed on the questionnaires to link the
confidential information to the subject. The master list linking subjects to their subject
numbers will also be kept in the locked cabinet, but separately.
During the study, the safety of the normal subjects will be maintained by: [1] the
presence of a physician at all times of testing; [2] careful direct physician observation and
monitoring of subjects during testing, and [3] instruction of subjects to immediately
discontinue the exercise and notify the physician should they experience any shortness of
breath, chest pain or pressure, dizziness, lightheadedness, or other unusual symptoms.
Emergency equipment will be present, and a physician will be in attendance for every
study patient.
If you have any of these or any other problems, notify your study doctor immediately. If
these side effects bother or worry you, or if you have other problems, call your study
doctor at (813) 974-7545. If you have an emergency, go to the closest emergency room
or clinic for treatment.
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You may also have problems from the medical treatment you would usually get.
We may need to stop your treatment. If we find that the breathing tests are causing
adverse events, we will stop the procedure. Early stopping criteria include:
1.

For individual subjects:
The following criteria will be used to discontinue participation in the
study:
[1] You wish to withdraw from the study.
[2] You do not meet the criteria for inclusion into the study.
[3] You demonstrate abnormalities on spirometry, physical
examination, or monitoring through the study.
[4] You complain of chest pain or pressure, palpitations, or
tachypnea.
[5] If you experience other symptoms, they will be assessed by a
doctor and assisted in any way needed. A decision will be made
whether you may continue to participate in the study provided that
your safety has not been compromised. In this case, the decision to
continue would require mutual willingness on your part to continue
the study.
[6] The safety of the researcher is compromised (for example, a
hostile subject).
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2.

For the study:
The study will be terminated if the health or safety of the volunteers
or examiners becomes jeopardized by an unforeseen event.
Is there any risk to your unborn children if you take part in this study?
Pregnant women will not be allowed to participate in the study. There are
no adverse effects for men with partners of childbearing age.
If you are a woman
You are excluded from the study if you are or may be pregnant due to the
study protocol, since the study results may be affected. If you are
pregnant and you inadvertently take part in this study, the risk of adverse
effects is still minimal, especially if you are in the first trimester of
pregnancy. Nonetheless, it could be that your unborn children may have
problems now or in the future.
Tell one of the study doctors right away if:
•

You are pregnant

•

You are breastfeeding.

If you are a woman
If you take part in this study, you must use a good birth control method, like oral
contraceptives or condoms.
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What if you get sick or hurt while you are in the study?
If you need emergency care:
•

Go to your nearest hospital or emergency room right away. Call 911 for help. It is
important that you tell the doctors at the hospital or emergency room that you are
participating in a research study. If possible, take a copy of this consent form with
you when you go. You should know that the USF does not provide emergency care.

•

Call the study doctors as soon as you can. They will need to know that you are hurt
or ill. Call Dr. Victor M. Nwiloh, MD or Dr. Stuart Brooks, MD at (813) 974-7545.

If it is NOT an emergency, and you get hurt or sick while you are taking part in this
study:
•

Go to your regular doctor. It is important that you tell your regular doctor that you
are participating in a research study. If possible, take a copy of this consent form
with you when you go.

•

The USF Medical Clinics may not be able to give the kind of help you need. You may
need to get help somewhere else.

If you are harmed while taking part in the study:
The state of Florida enjoys what is called "sovereign immunity." This means that you
usually cannot sue the state of Florida. However, the state has waived sovereign
immunity (agreed to be sued) in certain situations. One of those situations is if a state
employee, such as your study doctor or other USF employee, is negligent in doing his or
her job in a way that harms you during the study.
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The money that you might recover from the state of Florida is limited in amount.
You can also call the USF Self Insurance Programs (SIP) at 1-813-974-8008 if you think:
•

You were harmed because you took part in this study.

•

Someone from the study did something wrong that caused you harm, or didn’t do
something they should have done.

•

Ask the SIP to look into what happened.

What will we do to keep your study records private?
Federal law says we must keep your study records private. Private medical information
will be collected during the study to ascertain the health status of the subjects. The health
information is being collected only as a parameter for participation in the study. It is
obtained after discussion with the subjects that the study is only open to healthy subjects.
Thus, the questionnaires in the study must remain confidential. We will keep the records
of this study private by keeping them in a locked file cabinet. Access to the material will
only be made to the investigators of the study. Also, as an additional measure to ensure
confidentiality, each subject will be given a subject number. This will be the only
identifier listed on the questionnaires to link the confidential information to the subject.
The master list linking subjects to their subject numbers will also be kept in the locked
cabinet, but separately.
However, certain people may need to see your study records. By law, anyone who looks
at your records must keep them completely confidential.
The only people who will be allowed to see these records are:
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The medical staff who are taking care of you.
Certain government and university people who need to know more about the study. For
example, individuals who provide oversight on this study may need to look at your
records. These include the University of South Florida Institutional Review Board (IRB)
and the staff that work for the IRB. Other individuals who work for USF that provide
other kinds of oversight may also need to look at your records. Other individuals who
may look at your records include: the Florida Department of Health, people from the
Food and Drug Administration (FDA), the United States Department of Health and
Human Services, and the United States Department of Labor. This is done to make sure
that we are doing the study in the right way. They also need to make sure that we are
protecting your rights and your safety.)
People at the company who paid for this study at the Sunshine Education and Research
Center (funded by the National Institute of Occupational Safety and Health, a
governmental department under the United States Department of Labor may look at the
study records and pertinent portions of your medical records to make sure the study is
done in the right way.
We may publish what we find out from this study. If we do, we will not let anyone know
your name. We will not publish anything else that would let people know who you are.
What happens if you decide not to take part in this study?
You should only take part in this study if you want to take part.
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If you decide not to take part:
•

You will not be in trouble or lose any rights you normally have.

•

You will still have the same health care benefits.

•

You can still get your regular treatments from your regular doctor.

What if you join the study and decide you want to stop later on?
You can decide after signing this informed consent document that you no longer want to
take part in this study. If you decide you want to stop taking part in the study, tell the
study staff as soon as you can. If you decide to stop, you can continue getting care from
your regular doctor.
Are there reasons we might take you out of the study later on?
Even if you want to stay in the study, there may be reasons we will need to take you out
of it. You may be taken out of this study if:
•

We find out it is not safe for you to stay in the study. For example, your health may
worsen. Or we may find out that the device used to measure spirometry or exhaled
breath condensate might harm you. Then you may be taken out of the study.

•

You are not coming for your study visits when scheduled.

You can get the answers to your questions.
If you have any questions about this study, call Dr. Victor Nwiloh at (813) 974-7545.
If you have questions about your rights as a person who is taking part in a study, call the
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Division of Research Compliance of the University of South Florida at (813) 974-9343.
Signatures for Consent to Take Part in this Research Study
It is up to you to decide whether you want to take part in this study. If you want to take
part, please read the statements below and sign the form if the statements are true.
I freely give my consent to take part in this study. I understand that this I am agreeing to
take part in research. I have received a copy of this consent form to take with me.
I choose to participate in the study : a single visit which will last approximately ninety
minutes.
____________________________________________
Signature of Person Taking Part in Study

___________
Date

____________________________________________
Printed Name of Person Taking Part in Study
________________________________________
Signature of Witness

____________
Date

____________________________________________
Printed Name of Witness
Statement of Person Obtaining Informed Consent
I have carefully explained to the person taking part in the study what he or she can
expect.
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I hereby certify that when this person signs this form, to the best of my knowledge, he or
she understands:
What the study is about.
What needs to be done.
What the potential benefits might be.
What the known risks might be.
I also certify that he or she does not have any problems that could make it hard to
understand what it means to take part in this study. This person speaks the language
that was used to explain this study.
This person reads well enough to understand this form or, if not, this person is able to
hear and understand when the form is read to him or her.
This person does not have a medical problem that makes it hard to understand what is
being explained and can, therefore, give informed consent.
This person is not taking drugs that make it hard to understand what is being
explained and can, therefore, give informed consent.
____________________________________________

___________

Signature of Person Obtaining Informed Consent
__________________________________________________
Printed Name of Person Obtaining Informed Consent
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Date

____________________________________________
Signature of Witness

___________
Date

____________________________________________
Printed Name of Witness]
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